Skip to content

Evolution of Diaphragm Thickness Under Veno-arterial ECMO

Evolution of Diaphragm Thickness Under Veno-arterial ECMO : Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04052230
Acronym
ATROPHY-ECMO
Enrollment
30
Registered
2019-08-09
Start date
2019-10-13
Completion date
2022-04-19
Last updated
2023-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaphragm, Extracorporeal Membrane Oxygenation Complication

Keywords

diaphragm, ECMO, ICU

Brief summary

The main objective is to evaluate the evolution of the thickness of the diaphragm (during the first week of treatment) by VA ECMO in the resuscitation patients. The comprehension of the mechanisms involved in the diaphragm ailment will identify modifiable factors that lead to muscle degradation and thus to the deterioration of patients' prognosis.

Detailed description

The evolution of diaphragm muscle thickness is described in human resuscitation under mechanical ventilation, but the incidence, causes and functional impact have not been studied in patients undergoing cardiopulmonary bypass ECMO (extra-corporeal membrane oxygenation) veno-arterial (VA). More generally, the muscular mechanisms of dyspnea in cases of acute cardiac dysfunction are not known. The evolution of the diaphragmatic thickness in intensive care has been described during prolonged stay in intensive care and from the initial phase of septic status. It is associated with dyspnea, weaning delay of mechanical ventilation and impact on patient outcomes. The atrophy of the diaphragm muscle is related to both loss of function and loss of muscle performance. The same is true for hypertrophy that is caused by overuse of the muscle and also causes loss of function. Decreased cardiac muscle performance may require both cardiac assistance and respiratory assistance. Cardiac and respiratory dysfunction may complicate withdrawal of respiratory assistance and extracorporeal circulatory support devices. These two supports, respiratory and circulatory support, make it possible to mitigate the insufficiency of the systemic flow, the oxygenation and the purification of the CO2. Respiratory assistance is known to influence the diaphragmatic function. The role of muscle pump function in the weaning process of the ECMO, however, remains largely unknown. Ultrasound is used in the patient's bed in daily practice to measure cardiac function, the study of vessels but also the diaphragm muscle. It allows to study the trophicity of the diaphragm and these efforts via its contraction. The hypothesis that there is muscular involvement of the diaphragm in this measurable condition by ultrasound method can be formulated. No study has systematically explored the existence of diaphragmatic atrophy under VA ECMO. The influence of cardiac and respiratory assistance is not known. The purpose of this study is to provide a description of the diaphragm physiology of patients treated with VA ECMO. It is to evaluate the evolution of the trophicity of the diaphragm muscle in intensive care. Secondly, to evaluate the factors that influence it at the time of weaning. In this study it's planed to include a cohort of patients with a longitudinal evaluation of the thickness of the diaphragm during a cardiogenic shock under ECMO, and an evaluation of the influence of ECMO parameters and ventilation on the diaphragm.

Interventions

Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient hospitalized in intensive care * Patient under veno-arterial ECMO * Non-opposition of the patient or relatives * Affiliation to a health insurance

Exclusion criteria

* Subject under guardianship or subject deprived of liberty * Pregnant or lactating woman

Design outcomes

Primary

MeasureTime frameDescription
To evaluate the evolution of the trophicity of the diaphragm muscle during the first week of treatment with VA ECMO in patients in intensive care.Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7Evaluation of the trophicity of the diaphragm muscle at the end of the expiration from the first day in the intensive care unit after the ECMO implementation until the D7 of the hospitalization with ultrasound. A change greater than 10% of the thickness will define three groups of patients (loss of thickness, stability and thickness gain). The first day that this value is reached will determine the allocation in one or the other group.

Secondary

MeasureTime frameDescription
To evaluate the link between the evolution of respiratory physiological variables and the diaphragm evolution in patients in intensive care.Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7Measurement of the daily evolution of tidal volume during ultrasound collection
To evaluate the link between parameters of mechanical ventilation and the diaphragm evolution in patients in intensive careDay 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7Measurement of the daily ventilatory mode
To evaluate the evolution of the performance of the diaphragm muscle in patients in intensive care.Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7Measurement of the thickening fraction of the diaphragm.
To evaluate the link between the associated organ failures and the diaphragm evolution in patients in intensive careDay 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7The daily change in the incidence of diaphragmatic dysfunction defined by the diaphragm thickening fraction \<20% during a maximal inspiratory test to J7. The daily collection of hemodynamic variables during the diaphragmatic ultrasound collection including an evaluation of the visual LVEF.
To evaluate the impact of the diaphragm evolution on the future of the patient in intensive care: weaning of the assistances, survivals.and the diaphragmDay 60Measurement of the survival
To evaluate the link between the impact of ECMO parameters and the diaphragm evolution in patients in intensive careDay 1, Day 2, Day 3, Day 4, Day 5, Day 6, and Day 7Measurement of the daily the daily blood flow

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026